Adlai Nortye Ltd. (ANL)
ANL Stock Price Chart
Explore Adlai Nortye Ltd. interactive price chart. Choose custom timeframes to analyze ANL price movements and trends.
ANL Company Profile
Discover essential business fundamentals and corporate details for Adlai Nortye Ltd. (ANL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Sept 2023
Employees
123.00
Website
https://www.adlainortye.comCEO
Yang Lu
Description
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
ANL Financial Timeline
Browse a chronological timeline of Adlai Nortye Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $3.95m.
Earnings released on 29 Apr 2026
Earnings released on 10 Apr 2026
EPS came in at -$0.18 falling short of the estimated -$0.11 by -71.43%, while revenue for the quarter reached $5.30m .
Earnings released on 29 Dec 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 7 Aug 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 30 Apr 2025
EPS came in at -$0.22 surpassing the estimated -$0.53 by +58.49%.
Earnings released on 26 Feb 2025
EPS came in at -$0.22 surpassing the estimated -$0.53 by +58.49%.
Earnings released on 8 Aug 2024
EPS came in at -$0.53 surpassing the estimated -$1.06 by +50.15%, while revenue for the quarter reached $745.00k .
Earnings released on 20 Apr 2024
EPS came in at -$0.65 falling short of the estimated -$0.38 by -70.52%, while revenue for the quarter reached $2.50m .
Earnings released on 31 Mar 2024
EPS came in at -$0.53 , while revenue for the quarter reached $745.00k .
Earnings released on 30 Sept 2023
EPS came in at -$0.65 falling short of the estimated -$0.24 by -169.98%, while revenue for the quarter reached $2.50m , missing expectations by -50.00%.
Earnings released on 30 Jun 2023
EPS came in at -$2.49 .
Earnings released on 31 Mar 2023
EPS came in at -$0.59 .
Earnings released on 31 Dec 2022
EPS came in at -$0.87 .
Earnings released on 30 Sept 2022
EPS came in at -$0.87 .
Earnings released on 30 Jun 2022
EPS came in at -$0.14 .
Earnings released on 31 Mar 2022
EPS came in at -$0.44 .
ANL Stock Performance
Access detailed ANL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
